We are live on ! Find out more

Mid Cap Biotechnology
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
ALMS
51
Alumis Inc
ALMS
$3.1B
$3.1B $23.96 4.04%
ZLAB icon
52
Zai Lab
ZLAB
$2.94B
$2.94B $26.17 2.07%
SLS icon
53
SELLAS Life Sciences
SLS
$2.85B
$2.85B $14.09 1.67%
NRIX icon
54
Nurix Therapeutics
NRIX
$2.8B
$2.8B $26.95 2.59%
ATAI icon
55
AtaiBeckley Inc
ATAI
$2.76B
$2.76B $7.44 0.81%
VRDN icon
56
Viridian Therapeutics
VRDN
$2.74B
$2.74B $24.18 0.67%
GENB
57
Generate Biomedicines
GENB
$2.62B
$2.62B $20.38 15%
PHVS icon
58
Pharvaris
PHVS
$2.61B
$2.61B $37.23 0.21%
RARE icon
59
Ultragenyx Pharmaceutical
RARE
$2.61B
$2.61B $26.46 2.88%
PGEN icon
60
Precigen
PGEN
$2.61B
$2.61B $7.28 1.53%
NKTR icon
61
Nektar Therapeutics
NKTR
$2.56B
$2.56B $74.96 1.72%
TRVI icon
62
Trevi Therapeutics
TRVI
$2.56B
$2.56B $17.95 0.72%
VERA icon
63
Vera Therapeutics
VERA
$2.54B
$2.54B $35.28 4.63%
NUVB icon
64
Nuvation Bio
NUVB
$2.49B
$2.49B $7.10 5.03%
KOD icon
65
Kodiak Sciences
KOD
$2.48B
$2.48B $39.46 6.02%
RAPP
66
Rapport Therapeutics
RAPP
$2.46B
$2.46B $51.17 3.73%
OCUL icon
67
Ocular Therapeutix
OCUL
$2.39B
$2.39B $10.88 0.93%
MLYS icon
68
Mineralys Therapeutics
MLYS
$2.33B
$2.33B $26.34 4.23%
COAG
69
Hemab Therapeutics
COAG
$2.32B
$2.32B $49.65 6.39%
KLRA
70
Kailera Therapeutics
KLRA
$2.3B
$2.3B $17.75 7.32%
HRMY icon
71
Harmony Biosciences
HRMY
$2.27B
$2.27B $38.95 1.17%
URGN icon
72
UroGen Pharma
URGN
$2.27B
$2.27B $46.36 0.43%
MESO
73
Mesoblast
MESO
$2.23B
$2.23B $17.19 3.31%
AUPH icon
74
Aurinia Pharmaceuticals
AUPH
$2.23B
$2.23B $16.75 1.09%
VCEL icon
75
Vericel Corp
VCEL
$2.21B
$2.21B $43.22 2.17%
1 2
3
4

Mid Cap Biotechnology Stocks at a Glance

Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.

There are 84 mid cap Biotechnology stocks — companies in the Biotechnology industry with a market cap between $2B and $10B — worth a combined $356B.

The largest by market cap are Protagonist Therapeutics (PTGX) at $9.74B, Spyre Therapeutics (SYRE) at $9.47B and Vaxcyte (PCVX) at $9.09B.

Among institutional investors, Definium Therapeutics (DFTX) drew the most net new fund positions in Q2 2026: 148 funds opened new positions, taking total fund holders up 114 (46%) quarter-over-quarter.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.